MedStar Health Advances in Urologic Oncology 2026

Friday, October 16, 2026, 7:30 AM - Saturday, October 17, 2026, 5:00 PM, Park Hyatt D.C., Washington, DC

The MedStar Health Advances in Urologic Oncology 2026 conference is a two-day educational event designed for healthcare professionals involved in the diagnosis, treatment, and management of urologic cancers. The conference covers the latest advancements in prostate, bladder, and kidney cancers through lectures, interactive case-based tumor boards with audience polling, panel debates, and presentations from nationally recognized faculty. Attendees will gain practical knowledge of emerging therapies, evolving treatment paradigms, and value-based care considerations that can be applied directly to clinical practice.

Prostate Cancer: The prostate cancer sessions will cover advancements in diagnosis, local treatment, radiation, systemic therapy, and survivorship. Topics include the evolving role of genomic classifiers in guiding treatment decisions and personalizing management, advances in PSMA PET imaging and its impact on staging and treatment planning, and emerging techniques in transperineal biopsy. The expanding landscape of local treatment options will be explored, including focal therapy modalities, neoadjuvant radioligand therapy before radical prostatectomy, and surgical advances in functional outcomes. Modern radiation approaches will be addressed, including SBRT and ultra-hypofractionation, focal dose escalation, de-escalation strategies aimed at reducing toxicity while maintaining outcomes, and the integration of genomic classifiers and PSMA imaging into radiation treatment planning. The evidence for pelvic nodal irradiation in high-risk disease and the role of metastasis-directed SBRT for oligometastatic disease will also be reviewed.

Systemic therapy sessions will cover treatment intensification in metastatic hormone-sensitive disease, sequencing through castration-resistant disease, and PSMA-guided salvage strategies for biochemical recurrence. ADT survivorship topics including bone health, cardiovascular risk, and sexual health will be discussed. The day will close with a faculty debate on the role of pelvic lymph node dissection in the era of molecular imaging, followed by a session examining the cost, access, and equity implications of the innovations presented, helping attendees put new technologies and treatments into practical perspective.

Bladder Cancer: Bladder cancer management has seen significant advancements with the introduction of novel intravesical therapies and systemic treatments. The conference will provide clarity on treatment strategies for non-muscle invasive bladder cancer (NMIBC), including approaches for intermediate- and high-risk disease, surveillance and escalation pathways, and the expanding therapeutic options for BCG-unresponsive patients. Updates on the evolving perioperative treatment paradigm for muscle-invasive bladder cancer will be reviewed, including novel antibody-drug conjugate and immunotherapy combinations. The role of cystectomy versus bladder preservation strategies will be discussed, along with patient selection and quality-of-life considerations. The growing role of circulating biomarkers, including ctDNA and utDNA, will be reviewed for their application in surveillance, risk stratification, and perioperative decision support. The metastatic urothelial cancer treatment continuum will be explored, with sessions covering frontline and later-line sequencing strategies including antibody-drug conjugates, targeted therapies, and immunotherapy. A dedicated session on upper tract urothelial carcinoma will address risk stratification, kidney-sparing approaches, endoscopic management, intraluminal therapies, molecular profiling, and surgical decision-making.

Kidney Cancer: Kidney cancer, particularly renal cell carcinoma (RCC), presents significant challenges in both diagnosis and treatment. Sessions will cover management of the small renal mass, the role and timing of cytoreductive nephrectomy in metastatic disease, and advances in adjuvant immunotherapy for high-risk localized RCC. Strategies for managing metastatic RCC will be addressed, including first-line combination regimen selection, subsequent-line therapy sequencing, and emerging imaging modalities. A dedicated session on non-clear cell RCC will cover histology-driven treatment approaches for less common subtypes.

Multidisciplinary Care: The integration of multidisciplinary care is essential for optimizing patient outcomes in urologic oncology. The conference features interactive tumor boards with audience polling after every major clinical block, ensuring attendees engage with real cases across prostate, bladder, and kidney cancers in a collaborative format. A closing co-management panel will address the practical question of when the community urologist should treat, when to refer, and how to co-manage patients receiving systemic therapy across all three disease states.

1. Prostate Cancer Diagnosis and Imaging: Describe the role of PSMA PET imaging and transperineal biopsy techniques in diagnosing and staging prostate cancer, and how imaging findings guide treatment decisions across surgical, radiation, and systemic therapy pathways.
2. Genomic and Biomarker-Guided Decision-Making: Evaluate the current and emerging genomic classifiers and biomarker tools for assessing prostate cancer risk, guiding active surveillance decisions, and personalizing treatment selection across risk categories.
3. Localized Prostate Cancer Treatment Options: Compare the efficacy and suitability of focal therapy, surgical approaches, and radiation techniques including SBRT, ultra-hypofractionation, and focal dose escalation, incorporating evidence for de-escalation strategies that maintain outcomes while reducing toxicity.
4. Identify the roles and responsibilities of members of the healthcare team involved in the collaborative care of patients with urologic malignancies.
5. Neoadjuvant and Novel Therapeutic Strategies: Discuss the rationale and emerging evidence for neoadjuvant radioligand therapy before radical prostatectomy and its implications for high-risk localized prostate cancer management.
6. Management of Advanced and Metastatic Prostate Cancer: Discuss the latest approaches in systemic treatment of metastatic prostate cancer, including treatment intensification, PSMA-guided salvage strategies for biochemical recurrence, and sequencing through castration-resistant disease.
7. Radiation Advances in Prostate Cancer: Analyze modern radiation approaches including pelvic nodal irradiation for high-risk disease, metastasis-directed SBRT for oligometastatic disease, and how genomic classifiers and molecular imaging are being integrated into radiation treatment decisions.
8. Non-Muscle Invasive Bladder Cancer Therapeutics: Assess treatment strategies for intermediate- and high-risk NMIBC, including surveillance and escalation pathways, and evaluate the expanding therapeutic options for BCG-unresponsive disease.
9. Muscle-Invasive and Metastatic Bladder Cancer Management: Discuss the evolving perioperative treatment paradigm for muscle-invasive bladder cancer, evaluate cystectomy versus bladder preservation approaches, and apply sequencing strategies across the metastatic urothelial cancer treatment continuum.
10. Kidney Cancer Management: Identify appropriate management strategies for small renal masses, evaluate the role and timing of cytoreductive nephrectomy, and discuss the implications of adjuvant immunotherapy for high-risk localized RCC.
11. Advanced and Non-Clear Cell RCC: Discuss first-line and subsequent-line treatment decision-making in metastatic RCC and apply histology-driven treatment approaches for non-clear cell subtypes.
12. Multidisciplinary Case Analysis: Analyze management strategies for complex clinical scenarios through interactive multidisciplinary tumor boards across prostate, bladder, and kidney cancers.
13. Value-Based Care and Co-Management: Evaluate the cost, access, and equity implications of emerging urologic oncology treatments, and apply a practical framework for when to treat, refer, or co-manage patients receiving systemic therapy.

Early Bird Now thru September 7th

Physician: $125  
Resident and Fellow: Complimentary No Fee 
Physician Assistant: $50  
Nurse Practitioner: $50  
Nurse: $50  
Allied Health Professional: $50
Medical Student: Complimentary No Fee 
Industry Professional: $200
1-Day Pass: $75

September 8th - October 16th

Physician: $150  
Resident and Fellow: Complimentary No Fee 
Physician Assistant: $75 
Nurse Practitioner: $75 
Nurse: $75
Allied Health Professional: $75
Medical Student: Complimentary No Fee 
Industry Professional: $225
1-Day Pass: $90

In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education(ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



Credit Designation Statement:

  

This activity was planned by and for the healthcare team and learners will receive 12.75 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physicians: MedStar Health designates this live activity for a maximum of 12.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine MOC Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Surgery CC Credit

Successful completion of this CME activity, which includes participation in the evaluation and quiz component, enables the learner to earn credit toward the CME and Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

MOC Participation Threshold
Learner participates by completing a quiz with feedback and references to additional learning. The learner must pass the quiz with an 80% or higher to receive credit.

Nurses: This activity is approved for 12.75 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

The agenda and credits available are subject to change.

 

AMA PRA Category 1 Credits™ Physician (12.75 hours), ABIM MOC Part 2 (12.75 hours), ABS CC (12.75 hours), Interprofessional Continuing Education (12.75 hours), Non-Physician Member of the Healthcare Team (12.75 hours), Nurse - ANCC (12.75 hours), Physician Assistant - AAPA (12.75 hours)

 Park Hyatt Washington D.C.
1201 24th St. NW
Washington, D.C. 20037
202-789-1234

Click here to book a room at the Park Hyatt.

Mitigation of Relevant Financial Relationships

MedStar Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Individuals in a position to control the content of this CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships listed below have been mitigated prior to the commencement of the activity.

If you are interested in supporting the program, please contact Elizabeth Romano at [email protected]